Head-to-head evidence
GSK3862995 vs tozorakimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: IL-33 · full Chronic Obstructive Pulmonary Disease pipeline
GSK3862995
Developed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06154837 (registry estimate)
tozorakimab
Developed by AstraZeneca
NCT06040086 · Phase 3 · completed
The study was randomized, quadruple-blind, and placebo-controlled, with 1,454 participants, and evaluated a clinical exacerbation outcome. However, no primary endpoint results or statistical comparison are available, so the treatment effect cannot yet be judged.
Next expected readout: December 2028 · NCT07566195 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GSK3862995's landscape · tozorakimab's landscape